Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDI-118 First-in-Human Study in Healthy Males
NCT05486195Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SDI-118 (7 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with Adverse Events (AEs) at 21 Days, Number of participants with laboratory value abnormalities and/or adverse events at 21 Days and 5 more. Started Mar 2019; status: completed.
02
Drugs
SDI-118
Beyond the preview
Go deeper on NCT05486195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486195.